Q-omics provides the consensus-scored KLHDC4 profile across patient tissues and cancer cell-line models. KLHDC4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KLHDC4 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, KLHDC4 RNA expression shows 19,741 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where KLHDC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHDC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHDC4 survival associations across molecular data types. KLHDC4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHDC4 RNA expression–survival associations across cancer types. High KLHDC4 expression shows unfavorable associations in ACC, KIRC, LUSC and LIHC, but favorable associations in BLCA and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KLHDC4 RNA expression.
This table summarizes KLHDC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KLHDC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHDC4 shows higher tumor expression in KIRC, KIRP, COAD, STAD, LIHC and HNSC. The KIRC box plot shows higher KLHDC4 RNA expression in tumor versus normal tissue (log2 FC = +0.636, t-test p < 0.001).
This table shows molecular features associated with KLHDC4 in patient tissues and cancer cell lines. In patient samples, KLHDC4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHDC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
